trending Market Intelligence /marketintelligence/en/news-insights/trending/88rok7nvzzbztknfqvanpw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Paris court affirms lower ruling in Onxeo's JV dispute with SpePharm

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Paris court affirms lower ruling in Onxeo's JV dispute with SpePharm

The Court of Appeal of Paris has dismissed a request from Onxeo SA to review an earlier decision in its dispute with SpePharm Holding B.V. over the companies' 50-50 joint venture SpeBio BV.

SpeBio was formed to distribute Loramyc for the treatment of oropharyngeal candidiasis, a yeast or fungal infection.

Onxeo has alleged contract breaches by SpePharm and SpeBio that resulted in a delay in the marketing and sales of Loramyc. The alleged breach of contract caused Onxeo to terminate its agreement with the two companies in 2009 and litigate the matter.

The Commercial Court of Paris ruled against Onxeo in October 2017 and directed it to pay SpePharm and SpeBio €50,000 and €8.6 million in damages, respectively.

The Paris Court of Appeal has now affirmed the first ruling and ordered Onxeo to pay SpeBio an additional 2.8 million in compensation for costs incurred and loss of opportunity. The court, however, relieved Onxeo of paying the €50,000 in damages to SpePharm.

Onxeo owns half of SpeBio which amounts to €5 million in financial assets, and "should be able to retrieve half of the financial assets in the joint-venture," according to the company.

Paris-based Onxeo, a biotechnology company focused on cancer, will review its options following the court's decision and recalculate the financial impact the decision will have on the company.